Skip to main content
. 2014 Jul 8;9(7):e101819. doi: 10.1371/journal.pone.0101819

Figure 3. Overall survival for non-high-dose treated (non-HDT) patients with renal impairment.

Figure 3

(A) Patients treated with novel agents (bortezomib, thalidomide or lenalidomide) compared to conventional agents in the 1st treatment line. (B) Patients treated with bortezomib compared to conventional agents in the 1st treatment line.